Updates are available Correction dated 2021-02-09
Click to view Correction: https://doi.org/10.1038/s41591-021-01253-5
Updates are available Correction dated 2021-05-04
Click to view Correction: https://doi.org/10.1038/s41591-021-01367-w
-
Authors
Bernard, Elsa http://orcid.org/0000-0002-2057-7187
Nannya, Yasuhito
Hasserjian, Robert P.
Devlin, Sean M.
Tuechler, Heinz http://orcid.org/0000-0002-1568-3436
Medina-Martinez, Juan S.
Yoshizato, Tetsuichi http://orcid.org/0000-0003-4283-2983
Shiozawa, Yusuke
Saiki, Ryunosuke
Malcovati, Luca
Levine, Max F. http://orcid.org/0000-0001-5156-9086
Arango, Juan E.
Zhou, Yangyu
Solé, Francesc
Cargo, Catherine A.
Haase, Detlef
Creignou, Maria
Germing, Ulrich
Zhang, Yanming
Gundem, Gunes
Sarian, Araxe
van de Loosdrecht, Arjan A.
Jädersten, Martin
Tobiasson, Magnus
Kosmider, Olivier
Follo, Matilde Y. http://orcid.org/0000-0001-6126-0859
Thol, Felicitas
Pinheiro, Ronald F.
Santini, Valeria
Kotsianidis, Ioannis
Boultwood, Jacqueline http://orcid.org/0000-0002-4330-2928
Santos, Fabio P. S.
Schanz, Julie
Kasahara, Senji
Ishikawa, Takayuki
Tsurumi, Hisashi
Takaori-Kondo, Akifumi http://orcid.org/0000-0001-7678-4284
Kiguchi, Toru
Polprasert, Chantana
Bennett, John M.
Klimek, Virginia M.
Savona, Michael R. http://orcid.org/0000-0003-3763-5504
Belickova, Monika http://orcid.org/0000-0002-9158-881X
Ganster, Christina http://orcid.org/0000-0002-7566-5985
Palomo, Laura
Sanz, Guillermo http://orcid.org/0000-0002-2767-8191
Ades, Lionel
Della Porta, Matteo Giovanni
Elias, Harold K.
Smith, Alexandra G.
Werner, Yesenia
Patel, Minal
Viale, Agnès
Vanness, Katelynd
Neuberg, Donna S. http://orcid.org/0000-0003-2566-3145
Stevenson, Kristen E.
Menghrajani, Kamal
Bolton, Kelly L.
Fenaux, Pierre
Pellagatti, Andrea
Platzbecker, Uwe
Heuser, Michael http://orcid.org/0000-0001-5318-9044
Valent, Peter
Chiba, Shigeru
Miyazaki, Yasushi
Finelli, Carlo
Voso, Maria Teresa http://orcid.org/0000-0002-6164-4761
Shih, Lee-Yung
Fontenay, Michaela http://orcid.org/0000-0002-5492-6349
Jansen, Joop H.
Cervera, José
Atsuta, Yoshiko
Gattermann, Norbert
Ebert, Benjamin L. http://orcid.org/0000-0003-0197-5451
Bejar, Rafael http://orcid.org/0000-0002-5603-4598
Greenberg, Peter L.
Cazzola, Mario http://orcid.org/0000-0001-6984-8817
Hellström-Lindberg, Eva
Ogawa, Seishi http://orcid.org/0000-0002-7778-5374
Papaemmanuil, Elli http://orcid.org/0000-0003-1709-8983
- License Information
-
More Information
Article History
Received: 27 November 2019
Accepted: 7 July 2020
First Online: 3 August 2020
Change Date: 4 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-021-01367-w
Competing interests
: The authors declare the following competing interests. U.G. has received honoraria from Celgene, Novartis, Amgen, Janssen, Roche and Jazz and research funding from Celgene and Novartis. C.A.C. has received research funding from Celgene. A.A.L. is in advisory boards of Celgene, Amgen, Roche, Novartis and Alexion and has received research funding from Celgene. F.T. is on the advisory boards of Jazz, Pfizzer and Abbvie and has received research funding from Celgene. I.K. is on the advisory board of Genesis Pharma and has received research funding from Celgene and Janssen Hellas. F.P.S.S. has received honoraria from Janssen-Cilag, Bristol-Myers-Squibb, Novartis, Amgen, Abbvie and Pfizer, is on the advisory boards of Novartis, Amgen and Abbvie and has received research funding from Novartis. A.T.-K. has received honoraria from Novartis, Bristol-Myers-Squibb and MSD and has received research funding from Celgene, Ono Pharmaceutical and Cognano. T.K. has received research funding from Bristol-Myers-Squibb, Otsuka Pharmaceutical, Kyowa Kirin, MSD, Astellas Pharmaceutical, Nippon Shinyaku, Novartis Pharmaceutical, Sumitomo Dainippon Pharmaceutical, Janssen Pharmaceutical, Celgene, SymBio Pharmaceutical, Taiho Pharmaceutical, Tejin, Sanofi K.K. and Celltrion. M.R.S. is on the advisory boards of Abbvie, Astex, Celgene, Karyopharm, Selvita and TG Therapeutic, has equity in Karyopharm and has received research funding from Astex, Incyte, Sunesis, Takeda and TG Therapeutics. G.S. is on the advisory boards of AbbVie, Amgen, Astellas, Böehringer-Ingelheim, Celgene, Helsinn Healthcare, Hoffmann-La Roche, Janssen-Cilag, Novartis and Onconova and has received research funding from Celgene, Hoffmann-La Roche, Janssen-Cilag and Novartis. L.A. is on the advisory boards of Abbvie, Astex, Celgene and Novartis and has received research funding from Celgene. D.S.N. has equity in Madrigal Phamaceuticals and has received research funding from Celgene and Pharmacyclics. K.L.B. has received research funding from GRAIL. M.H. has received honoraria from Novartis, Pfizer and PriME Oncology, is on the advisory boards of Abbvie, Bayer Pharma, Daiichi Sankyo, Novartis and Pfizer and has received institutional research funding from Astellas, Bayer Pharma, BergenBio, Daiichi Sankyo, Karyopharm, Novartis, Pfizer and Roche. P.V. has received honoraria and research funding from Celgene. S.C. has received research funding from Kyowa Kirin, Chugai Pharmaceutical, Takeda Pharmaceutical, Astellas Pharmaceutical, Sanofi KK and Ono Pharmaceutical. Y.M. has received honoraria from Ohtsuka, Novartis, Nippon Shinyaku, Dainippon-Sumitomo and Kyowa Kirin and research funding from Chugai. C.F. is on the advisory boards of, and has received honoraria from, Celgene, Novartis and Janssen and has received research funding from Celgene. M.T.V. is on the advisory board of Celgene, has received honoraria from Celgene and Novartis and has received research funding from Celgene. Y.A. has received honoraria from Mochida, Meiji, Chugai and Kyowa Kirin. N.G. is on the advisory board of, and has received honoraria from, Novartis and has received research funding from Alexion. B.L.E. has received research funding from Celgene and Deerfield. R.B. is on the advisory boards of Celgene, AbbVie, Astex, NeoGenomics and Daiichi Sankyo and has received research funding from Celgene and Takeda. E.H.-L. has received research funding from Celgene. E.B. has received research funding from Celgene. E.P. has received research funding from Celgene and has served on scientific advisory boards for Novartis. E.P. is the founder and CEO of Isabl, a company offering analytics for cancer whole-genome sequencing data.
